Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer Edgardo RiveraMary Cianfrocca Review Article Open access 18 January 2015 Pages: 659 - 670
Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere John L. PilonDane J. ClausenRobert M. Williams Original Article 24 January 2015 Pages: 671 - 682
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study Roberto PetrioliGiandomenico RovielloEdoardo Francini Original Article 25 January 2015 Pages: 683 - 690
Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents Katharina MahalSebastian SchrueferMichael Höpfner Original Article 25 January 2015 Pages: 691 - 700
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease Emily ChanEunice L. KwakMonica Mita Original Article 28 January 2015 Pages: 701 - 709
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer Hyeong Su KimHo Young KimJoo Young Jung Original Article 29 January 2015 Pages: 711 - 718
Stabilization of the Karenitecin ® lactone by alpha-1 acid glycoprotein Shijie YaoPavankumar PetluruFrederick Hausheer Original Article 30 January 2015 Pages: 719 - 728
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258) Jeffrey R. InfanteRamesh K. RamanathanSunil Sharma Original Article 04 February 2015 Pages: 729 - 737
A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma Myeong Jun SongSi Hyun BaeJong Ryul Eun Original Article 07 February 2015 Pages: 739 - 746
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors David M. HymanAlexandra E. SnyderMatthew G. Fury Original Article 12 February 2015 Pages: 747 - 755
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer In Gyu HwangJoung-Soon JangKyong-Choun Chi Original Article 13 February 2015 Pages: 757 - 762
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy M. JoergerA. D. R. HuitemaJ. H. M. Schellens Original Article 13 February 2015 Pages: 763 - 772
Synthesis and biological evaluation of geldanamycin analogs against human cancer cells Yan-ping LiJin-jing ChenZhuo-rong Li Original Article 14 February 2015 Pages: 773 - 782
Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy Yu YangYang DuJi-Yan Liu Original Article 17 February 2015 Pages: 783 - 790
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients Eirini PanoiliaEmilie SchindlerGregory Sivolapenko Original Article Open access 17 February 2015 Pages: 791 - 803
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer Hirotoshi IshiwatariTsuyoshi HayashiJunji Kato Original Article 17 February 2015 Pages: 805 - 812
Serum metallothionein in patients with testicular cancer Blanka TaribaTanja ŽivkovićAlica Pizent Original Article 21 February 2015 Pages: 813 - 820
Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) P. KatsaounisA. KotsakisV. Georgoulias Original Article 22 February 2015 Pages: 821 - 827
Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy Kenta NioShuji AritaEishi Baba Original Article 22 February 2015 Pages: 829 - 835
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody Georgina Meneses-LorenteThomas FriessBirgit Bossenmaier Original Article Open access 22 February 2015 Pages: 837 - 850
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study Herbert I. HurwitzDavid C. SmithClaudio Zanna Original Article Open access 27 February 2015 Pages: 851 - 859
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer Yu-Wen HeMei-Ling ZhaoJian-Xing He Original Article 03 March 2015 Pages: 861 - 867
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer Mehmet Asim BilenSiqing FuAung Naing Clinical Trial Report 10 February 2015 Pages: 869 - 874
Delayed methotrexate excretion in infants and young children with central nervous system tumors and postoperative fluid collections Ian Cohen Letter to the Editor 12 February 2015 Pages: 875 - 875
Response to: comment on “Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections” Karen D. WrightClinton F. Stewart Letter to the Editor 26 February 2015 Pages: 877 - 878
